Patents
Patent Number: 7,473,414
Many interesting angles can be used to get patents. This patent covers the use of a mouse model for identifying factors associated with healing of wounds. These kind of patents make one wonder where exactly the limit of patentability is, and what is the purpose of actually filing the patent. The patent covers essentially what is described in the first independent claim: "A...
Inventors: Heber-Katz; Ellen (Philadelphia, PA)
Assignee: The Wistar Institute (Philadelphia, PA)
Date of First Priority Issue: Friday February 13th, 1998
Patent Number: 7,473,425
This patent essentially covers the combination of G-CSF with HGF, together with a clinically used pharmacotherapy, for the treatment of ischemic disease of a limb. Classically it has been difficult to induce therapeutically significant angiogenesis using single angiogenic compounds. Some companies are
using cells as secretors of angiogenic... Inventors: Fukuda; Keiichi (Tokyo, JP), Hisaka; Yasuyo (Tokyo, JP), Miyai; Tatsuya (Tokyo, JP), Tamura; Masahiko (Tokyo, JP)
Assignee: Fukuda Keiichi (Tokyo, JP)
Date of First Priority Issue: Thursday September 13th, 2001
Patent Number: 7,470,537
The therapeutic benefits of adipose derived stem cells have been demonstrated in animal trials and are currently undergoing several clinical trials. Although patents have been issued on methods of isolating fat derived stem cells, such as 7,390,484 held by Cytori, or
7,078,232 held by Artecel covering adipose stem cells that...
Inventors: Hedrick; Marc H. (Encino, CA), Katz; Adam J. (Charlottesville, VA), Llull; Ramon (Mallorca, Balearic Isles, ES), Futrell; J. William (Pittsburgh, PA), Benhaim; Prosper (Encino, CA), Lorenz; Hermann Peter (Belmont, CA), Zhu; Min (Los Angeles, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday March 10th, 1999
Patent Number: 7,470,425
There are many patents on
stem cells, or populations of stem cells, or
matrices for their delivery. This patent is interesting because it is a sort of a "hybrid patent". It is neither a patent on a matrix, or a patent on a cell. This patent covers a population of cells, that the...
Inventors: Vacanti; Charles A. (Uxbridge, MA), Vacanti; Joseph P. (Winchester, MA), Vacanti; Martin P. (Manhattan, KS)
Assignee: VBI Technologies, L.L.C. (Houston, TX)
Date of First Priority Issue: Wednesday November 25th, 1998
Patent Number: 7,470,538
The successful use of adult stem cells for treatment of cardiac conditions such as heart failure and post infarct recovery has been documented in
animal studies and
clinical trials. The current patent covers the use of one type of adult stem cell, cord blood stem cells for use in increasing perfusion in the myocardium. ...
Inventors: Laughlin; Mary J. (Shaker Heights, OH), Haynesworth; Stephen (Beachwood, OH), Pompili; Vincent (Hudson, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Date of First Priority Issue: Thursday December 5th, 2002
Patent Number: 7,468,277
This patent essentially covers a composition of purified human fetal multipotent neural stem cells that are isolated extracted directly from the brain of a human fetus without initial epidermal growth factor expansion. Specifically, the wherein the enriched preparation is capable of: (1) generating neurons, astrocytes, and oligodendrocytes and (2) being propagated for at least 7...
Inventors: Goldman; Steven A. (South Salem, NY), Okano; Hideyuki (Osaka, JP)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Thursday December 23rd, 1999
Patent Number: 7,468,276
This patent covers stem cells obtained from the placenta, in some ways similar to Hariri's other patents in this area such as #7,255,879
Post-partum mammalian placenta, its use and placental stem cells therefrom and #7,311,905
Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment... Inventors: Hariri; Robert J. (Florham Park, NJ)
Assignee: Anthrogenesis Corporation (Warren, NJ); part of Celgene
Date of First Priority Issue: Wednesday December 5th, 2001
Patent Number: 7,468,193
We at StemCellPatents.com have been seeing an increasing interest in "nutritional" modulation of the stem cell compartment. For example, patent # 7,338,676 teaches the use pine cone extracts for inducing differentiation of progenitor cells to dendritic cells. Patent #
6,814,961 covers the composition of blue...
Inventors: Schiffrin; Eduardo (Crissier, CH), Breuille; Denis (Epalinges, CH), Blum-Sperisen; Stephanie (Mont-Pelerin, CH), Donnet-Hughes; Anne (Saint-Legier, CH), Faure; Magali (Mollie-Margot, CH), Roessle; Claudia (Morges, CH), Turini; Marco Enrico (Epalinges, CH)
Assignee: Nestec S.A. (Vevey, CH)
Date of First Priority Issue: Thursday October 16th, 2003
Patent Number: 7,465,551
Since everyone is different in general, it makes little sense that people usually are all given "standard doses" of various medicines. Ideally one would like to be able to tailor doses to the specific needs of the patient. Thats what this patent covers.The patent covers "A method of determining a dose of G-CSF to be administered to a patient before or after a...
Inventors: Blumenthal; Rosalyn D. (Belleville, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee: Center For Molecular Medicine and Immunology (Belleville, NJ)
Date of First Priority Issue: Friday January 29th, 1999
1 Comment
Patent Number: 7,465,442
TGF-beta is a multi-functioning cytokine with activities in a variety of physiological processes, including
suppression of inflammation, protecting the
bone marrow from stress, and stimulation of
fibrosis. TGF-beta is known to inhibit cell cycle progression in part by turning on p21.sup.WAF1/Cip1...
Inventors: Gu; Danling (San Diego, CA), Zepeda; Monica (San Diego, CA)
Assignee: Canji, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday November 24th, 2003